According to the RNC Pharma® database “Audit of Retail Sales of Medicinal Products in Russia (total sell-out)”, in Q1–Q3 2025 the Russian retail market featured sales of nearly 6,000 pharmaceutical brands represented by 803 corporations. Over the first nine months of the year, the market volume for medicinal products reached RUB 1.36 trillion (in retail prices, including VAT), with value growth of 15.7% year-on-year compared to the same period in 2024.

Approximately 72% of the total retail market value was generated by the Top 50 corporations. Most of these can be classified as moderately dependent on their key products, where the share of the leading brand did not exceed 30% of the company’s total retail portfolio in value terms. However, there are also numerous examples of companies for which a single product accounts for more than half—or even the entirety—of their pharmaceutical revenue.

Among the Top 50 manufacturers, Pharmasoft stands out as being entirely concentrated on a single brand — Mexidol, which secured the top position in this ranking. The manufacturer registered the product in Russia in 2007; since then, multiple analogues have appeared on the market, yet Mexidol still accounts for more than 88% of value sales among brands containing the same active ingredient. The Pharmasoft portfolio also includes oral care products and a veterinary formulation, Mexidol-Vet.

In second place is Pfizer, whose flagship product Eliquis generates nearly 78% of the company’s retail sales — a share that has remained stable for several years. Jadran ranks third with Acnecutan, which contributed 69.5% of the company’s retail revenue in Q1–Q3 2025. The brand’s share in Jadran’s pharmaceutical portfolio increased by more than 13 percentage points year-on-year. It should be noted, however, that the company also has an extensive non-pharmaceutical portfolio, being among the leaders in nasal and throat irrigation products based on sea water and dry-eye relief solutions.

The strongest growth in the share of a leading product within the Top 10 was demonstrated by the Russian company Geropharm, whose drug Semavik accounted for 67.2% of total sales, up 22.4 percentage points compared to the same period of the previous year.

For three brands within the Top 10, the share of the leading product in company portfolios decreased over the year: Ursosan (PRO.MED.CS), Nurofen (Reckitt Benckiser), and Concor (Merck). On average, their shares declined by around 1 percentage point, although value sales for all three brands continued to grow steadily.

Among the Top 50 corporations, Bayer deserves particular mention: its brand Xarelto accounted for over 28% of retail sales a year ago, but following the entry of generic competitors, its share dropped to 22.1%, representing the sharpest decline among leading companies.

Top 10 Corporations with the Highest Dependence on a Key Pharmaceutical Brand in the Russian Retail Market, Q1–Q3 2025

among the Top 50 corporations by retail sales value